Health technology assessment (HTA) has been growing in use over the past 40 years,
especially in its impact on decisions regarding the reimbursement, adoption, and use of new …

Introduction: In Europe and beyond, the rising costs of healthcare and limited healthcare
resources have resulted in the implementation of health technology assessment (HTA) to …

The development of novel therapeutics for rare “orphan” diseases has brought a growing
tension between the desire to accelerate access to these breakthrough therapies and the …

Objectives To evaluate the national regulatory, health technology assessment (HTA), and
reimbursement pathways for public health care in Australia, Canada, England, and …

Access to medicines treating rare diseases ('orphan medicines') has proven challenging due
to high prices and clinical uncertainty. To optimise market access to these medicines, some …

Abstract Background In Canada, cost prohibits access to emergency contraception (EC)
which may assist to prevent unintended pregnancy. The drug, ulipristal acetate (UPA-EC), is …

Individuals who rely on public health payers to access new medicines can access fewer
innovative medicines and must wait longer in Canada compared to major markets around …

Background: Antiretrovirals are expensive and people living with HIV may experience a
range of financial burdens when accessing these medications. Our aim was to describe the …

Background Public payer reimbursement for non-oncology drugs in Canada, including
orphan drugs, is based on recommendations by the Common Drug Review (CDR)(with the …

Objectives Unlike other high-income countries, Canada has no national policy for drugs
treating rare diseases (orphan drugs). Nevertheless, in 2022, the Canadian government …